Management Strategies of Relapsed/Refractory Mantle Cell Lymphoma
Cancer Network,
Tycel Phillips, MD, reviewed effective second-line treatment options for patients with relapsed/refractory mantle cell lymphoma.
Pirtobrutinib, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated Mantle Cell Lymphoma: Updated Results from the Phase 1/2 BRUIN Study
Overview of attention for article published in Blood, November 2021
Altmetric Badge
About this Attention Score
-
In the top 25% of all research outputs scored by Altmetric
-
Good Attention Score compared to outputs of the same age (76th percentile)
-
Good Attention Score compared to outputs of the same age and source (67th percentile)
Readers on
- mendeley
- 40 Mendeley